Efficacy and costs of telehealth for the management of COPD: the PROMETE II trial. Issue 5 (31st May 2018)

• Record Type: Journal Article
• Authors: Ancochea, Julio; García-Río, Francisco; Vázquez-Espinosa, Emma; Hernando-Sanz, Ascensión; López-Yepes, Luis; Galera-Martínez, Raúl; Peces-Barba, Germán; Pérez-Warnisher, Maria Teresa; Segrelles-Calvo, Gonzalo; Zamarro, Celia; González-Ponce, Pablo; Ramos, M. Inmaculata; Conforto, Jose Ignacio; Jafri, Syed; Soriano, Joan B.
• Is Part Of: European respiratory journal. Volume 51:Issue 5(2018)
• Publication Date: 2018-05-31
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00354-2018
• Languages: English
• ISSNs: 0903-1936

Abstract

Chronic obstructive pulmonary disease (COPD) is a significant and largely underdiagnosed cause of morbidity and mortality worldwide [1]. More long-term survivors with advanced disease have led to an ageing COPD population profile with an increased level of acute exacerbations, hospitalisations and polymorbidity [2]. In the PROMETE II trial, telehealth did not reduce COPD-related use of health services http://ow.ly/KL7t30jotNb